Lactylation-driven FTO-mediated m6A modification of CDK2 aggravates diabetic microvascular anomalies
X. Chen, R.-X. Sun, J.-N. Wang, Y.-R. Zhang, B. Qin, Y.-C. Zhang, Y.-X. Dai, H.-J. Zhu, Y. Wang, J.-X. Zhao, W.-W. Zhang, J. Ji, S.-T. Yuan, Q.-D. Shen, Q.-H. Liu
This study shows that FTO, through lactylation-driven m6A modification of CDK2, worsens diabetic retinopathy by promoting angiogenesis and inflammation, and presents a nanotherapeutic approach to inhibit FTO.
bioRxiv · May 19, 2023 · PreprintCell Biology